News

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.

In addition to Prevent Blindness' usual free resources, the organization is providing a dedicated web page, fact sheets, and graphics in English and Spanish.

Yesafili is the first biosimilar to Eylea to be approved by Health Canada.

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop to treat people with neurotrophic keratitis.

All 696 patients in the trial have completed their treatment and follow-up visits.

Patients express mixed feelings about AI in health care, favoring its use for documentation and administrative tasks while demanding transparency and safety standards.

The VAC will be a strategic team informing Nanoscope’s scientific, clinical, and community-facing efforts.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

Andrew G. Lee, MD, and Drew Carey, MD, discuss how baseline optical coherence tomography parameters can help ophthalmologists counsel patients and make more informed decisions after ethambutol-associated optic neuropathy.